News | December 13, 2011

Bracco Updates Status of CardioGen-82 Recall, Third Patient Being Tested

December 13, 2011 – During RSNA 2011, Bracco explained it is working with the U.S. Food and Drug Administration (FDA) to re-introduce CardioGen-82 (Rubidium Rb 82 Generator) since its recall this past summer.

In July 2011, the U.S. Department of Homeland Security (DHS) notified the FDA about two individuals, who had previously undergone positron emissions tomography (PET) myocardial perfusion imaging (MPI) scans with CardioGen-82, crossing U.S. borders who triggered very sensitive gamma ray emission sensors. Full body scans of those two patients at Oak Ridge National Laboratory determined the estimated amount of unexpected radiation to be minimal and similar to what other patients may receive with cumulative exposure to certain other types of cardiac imaging procedures. Bracco’s investigation regarding a third patient detected at the border remains underway.

Maintaining its commitment to patient safety, Bracco has implemented several initiatives to ensure that its products meet the highest standards, including a voluntary recall of Rubidium (Rb) 82 Generators, a clinical assessment program and an Rb-82 Generator quality review program.

In support of a market return, Bracco is in the process of revalidating its manufacturing process and reviewing labeling and user training to ensure proper generator use. Bracco has been in constant communication with the FDA to investigate the root cause of the unexpected radiation detected in the border individuals and to address the FDA’s concerns.

Bracco has proposed an orderly, phased reintroduction of CardioGen-82 generators to user facilities, with data collection and evaluation of the actual field use of each generator. Based on the outcome of its reintroduction discussions with the FDA, Bracco anticipates a limited and progressive reintroduction of the product to commence in the first or second quarter of 2012.

For more information: www.cardiogen.com

Related Content

The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function.

Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function. Image courtesy of YaleNews.

News | PET Imaging | May 14, 2020
May 14, 2020 — New imaging technology allows scientists to see the widespread loss of brain synapses in early stages
Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group.

Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group. Image courtesy of Eric Berg, University of California, Davis, CA

News | PET Imaging | April 10, 2020
April 10, 2020 — Combining 89Zr-labeled antibodies with total-body...
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
MR Solutions’ dry magnet MRI system for molecular imaging on display at EMIM 2020
News | Magnetic Resonance Imaging (MRI) | February 28, 2020
February 28, 2020 — MR Solutions will be displaying its la
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a